Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;77(1):271-281.
doi: 10.1111/all.15007. Epub 2021 Jul 29.

Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort-19 study

Affiliations

Antibody response after one and two jabs of the BNT162b2 vaccine in nursing home residents: The CONsort-19 study

Hubert Blain et al. Allergy. 2022 Jan.

Abstract

Background: The humoral immune response following COVID-19 vaccination in nursing home residents is poorly known. A longitudinal study compared levels of IgG antibodies against the spike protein (S-RBD IgG) (S-RDB protein IgG) after one and two BNT162b2/Pfizer jabs in residents with and without prior COVID-19.

Methods: In 22 French nursing homes, COVID-19 was diagnosed with real-time reverse-transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2. Blood S-RDB-protein IgG and nucleocapsid (N) IgG protein (N-protein IgG) were measured 21-24 days after the first jab (1,004 residents) and 6 weeks after the second (820 residents).

Results: In 735 residents without prior COVID-19, 41.7% remained seronegative for S-RDB-protein IgG after the first jab vs. 2.1% of the 270 RT-PCR-positive residents (p < 0.001). After the second jab, 3% of the 586 residents without prior COVID-19 remained seronegative. However, 26.5% had low S-RDB-protein IgG levels (50-1050 UA/ml) vs. 6.4% of the 222 residents with prior COVID-19. Residents with an older infection (first wave), or with N-protein IgG at the time of vaccination, had the highest S-RDB-protein IgG levels. Residents with a prior COVID-19 infection had higher S-RDB-protein IgG levels after one jab than those without after two jabs.

Interpretation: A single vaccine jab is sufficient to reach a high humoral immune response in residents with prior COVID-19. Most residents without prior COVID-19 are seropositive for S-RDB-protein IgG after the second jab, but around 30% have low levels. Whether residents with no or low post-vaccine S-RDB protein IgG are at higher risk of symptomatic COVID-19 requires further analysis.

Keywords: BNT162b2/Pfizer vaccine; COVID-19; antibodies against SARS-CoV-2; nursing home; rRT-PCR.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest/competing interests.

Figures

FIGURE 1
FIGURE 1
Flow Diagram of the sample of residents from 22 nursing homes having faced a COVID‐19 outbreak between March and December 2020
FIGURE 2
FIGURE 2
Correlation between N‐ and S‐protein IgG depending on the time of the COVID‐19 infection, 3 weeks after the first jab. Legend: N‐protein IgG levels: positive value when ≥0.8 signal to cutoff ratio (vertical bars); S‐protein IgG levels: high values when ≥4160 arbitrary unit (AU)/ml (horizontal bar)

Similar articles

Cited by

References

    1. McMichael TM, Currie DW, Clark S, et al. Epidemiology of covid‐19 in a long‐term care facility in king county, Washington. N Engl J Med. 2020;382(21):2005‐2011. - PMC - PubMed
    1. Blain H, Rolland Y, Tuaillon E, et al. Efficacy of a test‐retest strategy in residents and health care personnel of a nursing home facing a COVID‐19 outbreak. J Am Med Dir Assoc.. 2020;21(7):933‐936. - PMC - PubMed
    1. Blain H, Rolland Y, Schols J, et al. August 2020 Interim EuGMS guidance to prepare European long‐term care facilities for COVID‐19. Eur Geriatr Med.. 2020;11(6):899‐913. - PMC - PubMed
    1. Jeffery‐Smith A, Iyanger N, Williams SV, et al. Antibodies to SARS‐CoV‐2 protect against re‐infection during outbreaks in care homes, September and October 2020. Euro Surveill. 2021;26(5):2100092. - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA covid‐19 Vaccine. N Engl J Med. 2020;383(27):2603‐2615. - PMC - PubMed